The business continues to lean heavily on the same familiar applications: NGS tools (53% of total revenue) and synthetic genes (31%). Twist Bioscience's recent foray into antibody discovery has stalled with revenue now back to early 2022 levels.

Whereas the bulk of revenue is dependent on only two applications, it's more diverse when viewed by customer group. Twist Bioscience is achieving similar rates of revenue growth across healthcare, industrial chemical, and academic accounts. This can be visualized by viewing the relative stability of revenue contributions from each customer group.